Judd W. Moul, MD

AddThis

Print

email this


Professor of Surgery
Professor in Anesthesiology
Director, Duke Prostate Center
James H. Semans, MD, Professor of Surgery
Department / Division:
Surgery / Urology
Address:
DUMC 3707
Durham, NC 27710
Appointment Telephone:
919-668-8108
Office Telephone:
919-684-5057
Fax:
919-684-8794
Training:
  • MD, Jefferson Medical College of Thomas Jefferson University (Pennsylvania), 1982
Residency:
  • Surgery, Walter Reed Army Medical Center (Washington, DC), 1982-1983
  • Urology, Walter Reed Army Medical Center (Washington, DC), 1983-1987
Fellowship:
  • Urologic Oncology, Duke University Medical Center, 1988-1989
Other Training:
  • BS, Pennsylvania State University, 1979
  • Fellow, American College of Surgeons
Clinical Interests:
Minimally invasive nerve-sparing radical prostatectomy, treatment of PSA-only or biochemical recurrence of prostate cancer, prostate cancer in African Americans, multidisciplinary management of prostate cancer, clinical trials in prostate disease, elevated PSA and screening, prostate cancer and outcomes/database research, elevated PSA and prostate cancer screening issues, active surveillance in early stage prostate cancer
Research Interests:
Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center.  He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology.  He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009.  He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer.  He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World.  He is very committed to training residents and mentoring students and trainees.
Representative Publications:
  • Boorjian, SA; Eastham, JA; Graefen, M; Guillonneau, B; Karnes, RJ; Moul, JW; Schaeffer, EM; Stief, C; Zorn, KC. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. European Urology. 2012;61:664-675.  Abstract
  • George, D; Moul, JW. Emerging treatment options for patients with castration-resistant prostate cancer. The Prostate. 2012;72:338-349.  Abstract
  • Loeb, S; Carter, HB; Catalona, WJ; Moul, JW; Schroder, FH. Baseline prostate-specific antigen testing at a young age. European Urology. 2012;61:1-7.  Abstract
  • Moul, JW. Prostate cancer: making the switch from LHRH antagonist to LHRH agonist. Nature Reviews Urology. 2012;9:125-126.  Abstract
  • Moul, JW; Dawson, N. Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. Cancer Investigation (Informa). 2012;30:1-12.  Abstract
  • Schroeck, FR; Krupski, TL; Stewart, SB; Bañez, LL; Gerber, L; Albala, DM; Moul, JW. Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy. The Journal of Urology. 2012;187:894-898.  Abstract
  • Stewart, SB; Bañez, LL; Robertson, CN; Freedland, SJ; Polascik, TJ; Xie, D; Koontz, BF; Vujaskovic, Z; Lee, WR; Armstrong, AJ; Febbo, PG; George, DJ; Moul, JW. Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. The Journal of Urology. 2012;187:103-108.  Abstract
  • Tang, P; Du, W; Xie, K; Fu, J; Chen, H; Yang, W; Moul, JW. Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences. The Prostate. 2012;72:173-180.  Abstract
  • Tsivian, M; Moreira, DM; Sun, L; Mouraviev, V; Kimura, M; Moul, JW; Polascik, TJ. Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. Urologic Oncology: seminars and original investigations. 2012;30:21-25.  Abstract
  • Wattson, DA; Chen, MH; Moran, BJ; Dosoretz, DE; Braccioforte, MH; Salenius, SA; D'Amico, AV. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. International Journal of Radiation: Oncology - Biology - Physics. 2012;82:e773-e779.  Abstract
  • Arvold, ND; Chen, MH; Moul, JW; Moran, BJ; Dosoretz, DE; Bañez, LL; Katin, MJ; Braccioforte, MH; D'Amico, AV. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. The Journal of Urology. 2011;186:91-96.  Abstract
  • Chu, DI; De Nunzio, C; Gerber, L; Thomas, JA; Calloway, EE; Albisinni, S; Senocak, C; McKeever, MG; Moreira, DM; Tubaro, A; Moul, JW; Freedland, SJ; Bañez, LL. Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. Prostate Cancer and Prostatic Diseases. 2011;14:346-353.  Abstract
  • Cotter, SE; Chen, MH; Moul, JW; Lee, WR; Koontz, BF; Anscher, MS; Robertson, CN; Walther, PJ; Polascik, TJ; D'Amico, AV. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011;117:3925-3932.  Abstract
  • Crawford, ED; Moul, JW; Rove, KO; Pettaway, CA; Lamerato, LE; Hughes, A. Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone. Bju International. 2011;108:1743-1749.  Abstract
  • Dreicer, R; Bajorin, DF; McLeod, DG; Petrylak, DP; Moul, JW. New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. Urology. 2011;78:S494-S498.  Abstract
  • Fu, Q; Moul, JW; Sun, L. Contemporary radical prostatectomy. Prostate Cancer. 2011;2011:645030.  Abstract
  • Moul, JW; Evans, CP; Gomella, LG; Roach, M; Dreicer, R. Traditional approaches to androgen deprivation therapy. Urology. 2011;78:S485-S493.  Abstract
  • Reed, SD; Scales Jr, CD; Stewart, SB; Sun, J; Moul, JW; Schulman, KA; Xu, J. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. The Journal of Urology. 2011;185:841-847.  Abstract
  • Tang, P; Sun, L; Uhlman, MA; Robertson, CN; Polascik, TJ; Moul, JW. Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men. Bju International. 2011;108:44-48.  Abstract
  • Ali, A; Furusato, B; Ts'o, PO; Lum, ZP; Elsamanoudi, S; Mohamed, A; Srivastava, S; Moul, JW; Brassell, SA; Sesterhenn, IA; McLeod, DG. Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors. Pathology International. 2010;60:667-672.  Abstract
  • Caire, AA; Sun, L; Lack, BD; Lum, K; Tang, P; Stackhouse, DA; Robertson, CN; Mouraviev, V; Polascik, TJ; Albala, DM; Moul, JW. Predicting non-organ-confined prostate cancer in men diagnosed after 2000. Prostate Cancer and Prostatic Diseases. 2010;13:248-251.  Abstract
  • Caire, AA; Sun, L; Polascik, TJ; Albala, DM; Moul, JW. Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans. Bju International. 2010;106:1157-1160.  Abstract
  • Caire, AA; Sun, L; Robertson, CN; Polascik, TJ; Maloney, KE; George, DJ; Price, MM; Stackhouse, DA; Lack, BD; Albala, DM; Moul, JW. Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology. 2010;75:1122-1127.  Abstract
  • Caso, JR; Mouraviev, V; Tsivian, M; Polascik, TJ; Moul, JW. Prostate cancer: an evolving paradigm. Journal of Endourology. 2010;24:805-809.  Abstract
  • Caso, JR; Tsivian, M; Mouraviev, V; Polascik, TJ; Moul, JW. Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. Bju International. 2010;106:1623-1627.  Abstract
  • D'Amico, AV; Chen, MH; Sun, L; Lee, WR; Mouraviev, V; Robertson, CN; Walther, PJ; Polascik, TJ; Albala, DM; Moul, JW. Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. Bju International. 2010;106:1618-1622.  Abstract
  • Droz, JP; Balducci, L; Bolla, M; Emberton, M; Fitzpatrick, JM; Joniau, S; Kattan, MW; Monfardini, S; Moul, JW; Naeim, A; van Poppel, H; Saad, F; Sternberg, CN. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Critical Reviews in Oncology Hematology. 2010;73:68-91.  Abstract
  • Droz, JP; Balducci, L; Bolla, M; Emberton, M; Fitzpatrick, JM; Joniau, S; Kattan, MW; Monfardini, S; Moul, JW; Naeim, A; van Poppel, H; Saad, F; Sternberg, CN. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. Bju International. 2010;106:462-469.  Abstract
  • Jayachandran, J; Schroeck, F; Sun, L; Gerber, L; Moreira, DM; Moul, JW; Freedland, SJ. The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: validation in the Duke Prostate Center database. Bju International. 2010;105:180-184.  Abstract
  • Moreira, DM; Presti, JC; Aronson, WJ; Terris, MK; Kane, CJ; Amling, CL; Sun, LL; Moul, JW; Freedland, SJ. The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Prostate Cancer and Prostatic Diseases. 2010;13:87-93.  Abstract
  • Moul, JW. Radiotherapy: Secondary malignancies after prostate cancer treatment. Nature Reviews Clinical Oncology. 2010;7:249-250.  Abstract
  • Moul, JW; Tang, P; Sun, L. Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. European Urology. 2010;57:452.  Abstract
  • Schroeck, FR; Kattan, MW; Moul, JW; Aronson, WJ; Presti, JC; Terris, MK; Kane, CJ; Amling, CL; Sun, L; Freedland, SJ. Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. Bju International. 2010;105:1654-1659.  Abstract
  • Tang, P; Sun, L; Uhlman, MA; Polascik, TJ; Freedland, SJ; Moul, JW. Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Cancer. 2010;116:4711-4717.  Abstract
  • Tang, P; Sun, L; Uhlman, MA; Robertson, CN; Polascik, TJ; Albala, DM; Donatucci, CF; Moul, JW. Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. The Journal of Urology. 2010;183:946-950.  Abstract
  • Uhlman, MA; Sun, L; Stackhouse, DA; Caire, AA; Polascik, TJ; Robertson, CN; Madden, J; Vollmer, R; Albala, DM; Moul, JW. Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?. Urology. 2010;75:460-466.  Abstract
  • Uhlman, MA; Sun, L; Stackhouse, DA; Polascik, TJ; Mouraviev, V; Robertson, CN; Albala, DM; Moul, JW. Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. The Journal of Urology. 2010;183:997-1001.  Abstract
  • Bañez, LL; Blake, GW; McLeod, DG; Crawford, ED; Moul, JW. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. Bju International. 2009;104:310-314.  Abstract
  • Bañez, LL; Sun, L; Trock, BJ; Han, M; Partin, AW; Aronson, WJ; Terris, MK; Presti, JC; Kane, CJ; Amling, CL; Moul, JW; Freedland, SJ. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. The Journal of Urology. 2009;182:491-496.  Abstract
  • Caire, AA; Sun, L; Ode, O; Stackhouse, DA; Maloney, K; Donatucci, C; Mouraviev, V; Polascik, TJ; Robertson, CN; Albala, DM; Moul, JW. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?. Urology. 2009;74:643-647.  Abstract
  • Chen, VH; Mouraviev, V; Mayes, JM; Sun, L; Madden, JF; Moul, JW; Polascik, TJ. Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection. Technology in cancer research & treatment. 2009;8:99-104.  Abstract
  • Chino, J; Schroeck, FR; Sun, L; Lee, WR; Albala, DM; Moul, JW; Koontz, BF. Robot-assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy. Bju International. 2009;104:1496-1500.  Abstract
  • D'Alonzo, RC; Gan, TJ; Moul, JW; Albala, DM; Polascik, TJ; Robertson, CN; Sun, L; Dahm, P; Habib, AS. A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy. Journal of Clinical Anesthesia. 2009;21:322-328.  Abstract
  • Freedland, SJ; Bañez, LL; Sun, LL; Fitzsimons, NJ; Moul, JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer and Prostatic Diseases. 2009;12:259-263.  Abstract
  • Habib, AS; Polascik, TJ; Weizer, AZ; White, WD; Moul, JW; ElGasim, MA; Gan, TJ. Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy. Anesthesia and Analgesia. 2009;108:1950-1953.  Abstract
  • Moul, JW. Innovations in urology from military medicine. Urologic Oncology: seminars and original investigations. 2009;27:551-552.  Abstract
  • Moul, JW. Post-radical prostatectomy management options for positive surgical margins: argument for observation. Urologic Oncology: Seminars and Original Investigations. 2009;27:92-96.  Abstract
  • Moul, JW. Report from Durham. Prostate Cancer and Prostatic Diseases. 2009;12:209-210.  Abstract
  • Moul, JW. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer. 2009;115:3376-3378.  Abstract
  • Moul, JW. Twenty-five year evolution of medical hormonal therapy for prostate cancer. Bju International. 2009;103:145-146.  Abstract
  • Moul, JW. Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example. European Urology. 2009;55:1266-1268.  Abstract
  • Moul, JW; Mouraviev, V; Sun, L; Schroeck, FR; Polascik, TJ. Prostate cancer: the new landscape. Current Opinion in Urology. 2009;19:154-160.  Abstract
  • Nguyen, PL; Chen, MH; Catalona, WJ; Moul, JW; Sun, L; D'Amico, AV. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. International Journal of Radiation: Oncology - Biology - Physics. 2009;73:659-664.  Abstract
  • Polascik, TJ; Mayes, JM; Schroeck, FR; Sun, L; Madden, JF; Moul, JW; Mouraviev, V. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer. 2009;115:2104-2110.  Abstract
  • Stackhouse, DA; Sun, L; Schroeck, FR; Jayachandran, J; Caire, AA; Acholo, CO; Robertson, CN; Albala, DM; Polascik, TJ; Donatucci, CF; Maloney, KE; Moul, JW. Factors predicting prostatic biopsy Gleason sum under grading. The Journal of Urology. 2009;182:118-122.  Abstract
  • Sun, L; Caire, AA; Robertson, CN; George, DJ; Polascik, TJ; Maloney, KE; Walther, PJ; Stackhouse, DA; Lack, BD; Albala, DM; Moul, JW. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. The Journal of Urology. 2009;182:2242-2248.  Abstract
  • Tsivian, M; Sun, L; Mouraviev, V; Madden, JF; Mayes, JM; Moul, JW; Polascik, TJ. Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology. 2009;74:1090-1093.  Abstract
  • Xu, DD; Sun, SD; Wang, F; Sun, L; Stackhouse, D; Polascik, T; Albala, DM; Moul, JW; Caire, A; Robertson, CN. Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. Urology. 2009;74:654-658.  Abstract
  • Demark-Wahnefried, W; Polascik, TJ; George, SL; Switzer, BR; Madden, JF; Ruffin, MT; Snyder, DC; Owzar, K; Hars, V; Albala, DM; Walther, PJ; Robertson, CN; Moul, JW; Dunn, BK; Brenner, D; Minasian, L; Stella, P; Vollmer, RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008;17:3577-3587.  Abstract
  • Freedland, SJ; Sun, L; Kane, CJ; Presti, JC; Terris, MK; Amling, CL; Moul, JW; Aronson, WJ. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Bju International. 2008;102:969-974.  Abstract
  • Habib, AS; White, WD; El Gasim, MA; Saleh, G; Polascik, TJ; Moul, JW; Gan, TJ. Transdermal nicotine for analgesia after radical retropubic prostatectomy. Anesthesia and Analgesia. 2008;107:999-1004.  Abstract
  • Isariyawongse, BK; Sun, L; Bañez, LL; Robertson, C; Polascik, TJ; Maloney, K; Donatucci, C; Albala, D; Mouraviev, V; Madden, JF; Moul, JW. Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology. 2008;72:882-886.  Abstract
  • Moul, JW. Are we overtreating prostate cancer?. The Journal of Urology. 2008;180:2299-2300.  Abstract
  • Moul, JW. Point: radical prostatectomy is the treatment of choice for high-risk prostate cancer patients. Brachytherapy. 2008;7:277-279.  Abstract
  • Moul, JW. Report from Durham. Prostate Cancer and Prostatic Diseases. 2008;11:1.  Abstract
  • Moul, JW. Report from Durham. Prostate Cancer and Prostatic Diseases. 2008;11:211.  Abstract
  • Moul, JW. Words of wisdom. Re: obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. European Urology. 2008;54:232-233.  Abstract
  • Moul, JW; Wu, H; Sun, L; McLeod, DG; Amling, C; Donahue, T; Kusuda, L; Sexton, W; O'Reilly, K; Hernandez, J; Chung, A; Soderdahl, D. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. The Journal of Urology. 2008;179:S53-S59.  Abstract
  • Mouraviev, V; Broadwater, G; Sun, L; Mayes, JM; Moul, JW; Polascik, TJ. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?. Urology. 2008;71:1020-1023.  Abstract
  • Polascik, TJ; Mayes, JM; Sun, L; Madden, JF; Moul, JW; Mouraviev, V. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. The Prostate. 2008;68:1380-1386.  Abstract
  • Rampersaud, EN; Sun, L; Moul, JW; Madden, J; Freedland, SJ. Percent tumor involvement and risk of biochemical progression after radical prostatectomy. The Journal of Urology. 2008;180:571-576.  Abstract
  • Scales, CD; Antonelli, J; Curtis, LH; Schulman, KA; Moul, JW. Prostate-specific antigen screening among young men in the United States. Cancer. 2008;113:1315-1323.  Abstract
  • Schroeck, FR; Donatucci, CF; Smathers, EC; Sun, L; Albala, DM; Polascik, TJ; Moul, JW; Krupski, TL. Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer. 2008;113:2687-2694.  Abstract
  • Schroeck, FR; Krupski, TL; Sun, L; Albala, DM; Price, MM; Polascik, TJ; Robertson, CN; Tewari, AK; Moul, JW. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. European Urology. 2008;54:785-793.  Abstract
  • Schroeck, FR; Sun, L; Freedland, SJ; Albala, DM; Mouraviev, V; Polascik, TJ; Moul, JW. Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. Bju International. 2008;102:28-32.  Abstract
  • Schroeck, FR; Sun, L; Freedland, SJ; Jayachandran, J; Robertson, CN; Moul, JW. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer and Prostatic Diseases. 2008;11:371-376.  Abstract
  • Schroeck, FR; de Sousa, CA; Kalman, RA; Kalia, MS; Pierre, SA; Haleblian, GE; Sun, L; Moul, JW; Albala, DM. Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss, and positive surgical margin rate. Urology. 2008;71:597-601.  Abstract
  • Weinrich, SP; Seger, RE; Rao, GS; Chan, EC; Hamm, RM; Godley, PA; Moul, JW; Powell, IJ; Chodak, GW; Taylor, KL; Weinrich, MC. A decision aid for teaching limitations of prostate cancer screening. Journal of National Black Nurses' Association. 2008;19:1-11.  Abstract
  • Whittemore, DE; Hick, EJ; Carter, MR; Moul, JW; Miranda-Sousa, AJ; Sexton, WJ. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. The Journal of Urology. 2008;179:516-522.  Abstract
  • Bañez, LL; Hamilton, RJ; Partin, AW; Vollmer, RT; Sun, L; Rodriguez, C; Wang, Y; Terris, MK; Aronson, WJ; Presti, JC; Kane, CJ; Amling, CL; Moul, JW; Freedland, SJ. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA : the journal of the American Medical Association. 2007;298:2275-2280.  Abstract
  • Burnett, AL; Aus, G; Canby-Hagino, ED; Cookson, MS; D'Amico, AV; Dmochowski, RR; Eton, DT; Forman, JD; Goldenberg, SL; Hernandez, J; Higano, CS; Kraus, S; Liebert, M; Moul, JW; Tangen, C; Thrasher, JB; Thompson, I; American Urological Association Prostate Cancer Guideline Update Panel. Erectile function outcome reporting after clinically localized prostate cancer treatment. The Journal of Urology. 2007;178:597-601.  Abstract
  • Cookson, MS; Aus, G; Burnett, AL; Canby-Hagino, ED; D'Amico, AV; Dmochowski, RR; Eton, DT; Forman, JD; Goldenberg, SL; Hernandez, J; Higano, CS; Kraus, SR; Moul, JW; Tangen, C; Thrasher, JB; Thompson, I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. The Journal of Urology. 2007;177:540-545.  Abstract
  • D'Amico, AV; Chen, MH; Catalona, WJ; Sun, L; Roehl, KA; Moul, JW. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer. 2007;110:56-61.  Abstract
  • Fitzsimons, NJ; Sun, L; Moul, JW. Medical technologies for the diagnosis of prostate cancer. Expert Review of Medical Devices. 2007;4:227-239.  Abstract
  • Fitzsimons, NJ; Sun, LL; Dahm, P; Moul, JW; Madden, J; Gan, TJ; Freedland, SJ. A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database. Urology. 2007;70:1146-1151.  Abstract
  • Freedland, SJ; Moul, JW. Prostate specific antigen recurrence after definitive therapy. The Journal of Urology. 2007;177:1985-1991.  Abstract
  • Moul, JW. Timely diagnosis of testicular cancer. Urologic Clinics of North America. 2007;34:109-117.  Abstract
  • Moul, JW; Bañez, LL; Freedland, SJ. Rising PSA in nonmetastatic prostate cancer. Oncology. 2007;21:1436-1445.  Abstract
  • Moul, JW; Sun, L; Hotaling, JM; Fitzsimons, NJ; Polascik, TJ; Robertson, CN; Dahm, P; Anscher, MS; Mouraviev, V; Pappas, PA; Albala, DM. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. The Journal of Urology. 2007;177:499-503.  Abstract
  • Mouraviev, V; Mayes, JM; Sun, L; Madden, JF; Moul, JW; Polascik, TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 2007;110:906-910.  Abstract
  • Mouraviev, V; Nosnik, I; Sun, L; Robertson, CN; Walther, P; Albala, D; Moul, JW; Polascik, TJ. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology. 2007;69:311-314.  Abstract
  • Mouraviev, V; Sun, L; Madden, JF; Mayes, JM; Moul, JW; Polascik, TJ. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Urology. 2007;70:1141-1145.  Abstract
  • Nosnik, IP; Gan, TJ; Moul, JW. Open radical retropubic prostatectomy 2007: the true minimally invasive surgery for localized prostate cancer?. Expert Review of Anticancer Therapy. 2007;7:1309-1317.  Abstract
  • Robinson, MR; Moul, JW. Novel techniques for the treatment of localized prostate cancer: evidence of efficacy?. Current Urology Reports. 2007;8:203-210.  Abstract
  • Scales, CD; Curtis, LH; Norris, RD; Schulman, KA; Dahm, P; Moul, JW. Relationship between body mass index and prostate cancer screening in the United States. The Journal of Urology. 2007;177:493-498.  Abstract
  • Scales, CD; Moul, JW; Curtis, LH; Elkin, EP; Hughes, ME; Carroll, PR; CaPSURE Investigators. Prostate cancer in the Baby Boomer generation: results from CaPSURE. Urology. 2007;70:1162-1167.  Abstract
  • Sun, L; Moul, JW; Hotaling, JM; Rampersaud, E; Dahm, P; Robertson, C; Fitzsimons, N; Albala, D; Polascik, TJ. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. Bju International. 2007;99:753-757.  Abstract
  • Thompson, I; Thrasher, JB; Aus, G; Burnett, AL; Canby-Hagino, ED; Cookson, MS; D'Amico, AV; Dmochowski, RR; Eton, DT; Forman, JD; Goldenberg, SL; Hernandez, J; Higano, CS; Kraus, SR; Moul, JW; Tangen, CM; AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. The Journal of Urology. 2007;177:2106-2131.  Abstract
  • Tseng, TY; Cancel, QV; Fesperman, SF; Kuebler, HR; Sun, L; Robertson, CN; Polascik, TJ; Moul, JW; Vieweg, J; Albala, DM; Dahm, P. The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy. The Journal of Urology. 2007;177:1318-1323.  Abstract
  • Anscher, MS; Clough, R; Robertson, CN; Prosnitz, LR; Dahm, P; Walther, P; Donatucci, CF; Albala, DM; Febbo, P; George, DJ; Sun, L; Moul, JW. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Prostate Cancer and Prostatic Diseases. 2006;9:254-260.  Abstract
  • Efstathiou, JA; Chen, MH; Catalona, WJ; McLeod, DG; Carroll, PR; Moul, JW; Roehl, KA; D'Amico, AV. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology. 2006;68:342-347.  Abstract
  • Freedland, SJ; Krupski, TL; Moul, JW. Update on outcomes research databases in prostate cancer 2006. Current Opinion in Urology. 2006;16:168-172.  Abstract
  • Lee, WR; Moul, JW. Can prostate-specific antigen nadir predict prostate cancer outcomes following radiotherapy?. Nature Clinical Practice Oncology. 2006;3:534-535.  Abstract
  • Merseburger, AS; Hennenlotter, J; Simon, P; Müller, CC; Kühs, U; Knüchel-Clarke, R; Moul, JW; Stenzl, A; Kuczyk, MA. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncology Reports: an international journal devoted to fundamental and applied research in oncology. 2006;16:79-83.  Abstract
  • Moul, JW. Treatment of PSA only recurrence of prostate cancer after prior local therapy. Current Pharmaceutical Design. 2006;12:785-798.  Abstract
  • Moul, JW; Ward, JF. Management of the patient with a rising PSA alone. Hematology/Oncology Clinics of North America. 2006;20:897-908.  Abstract
  • Scales, CD; Curtis, LH; Norris, RD; Schulman, KA; Albala, DM; Moul, JW. Prostate specific antigen testing in men older than 75 years in the United States. The Journal of Urology. 2006;176:511-514.  Abstract
  • Sun, M; Srikantan, V; Ma, L; Li, J; Zhang, W; Petrovics, G; Makarem, M; Strovel, JW; Horrigan, SG; Augustus, M; Sesterhenn, IA; Moul, JW; Chandrasekharappa, S; Zou, Z; Srivastava, S. Characterization of frequently deleted 6q locus in prostate cancer. DNA and Cell Biology. 2006;25:597-607.  Abstract
  • Tseng, TY; Sevilla, DW; Moul, JW; Maloney, KE. Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report. Prostate Cancer and Prostatic Diseases. 2006;9:195-197.  Abstract
  • Xu, LL; Sun, C; Petrovics, G; Makarem, M; Furusato, B; Zhang, W; Sesterhenn, IA; McLeod, DG; Sun, L; Moul, JW; Srivastava, S. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer and Prostatic Diseases. 2006;9:56-61.  Abstract
  • Bañez, LL; Srivastava, S; Moul, JW. Proteomics in prostate cancer. Current Opinion in Urology. 2005;15:151-156.  Abstract
  • Brassell, SA; Kao, TC; Sun, L; Moul, JW. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology. 2005;66:1229-1233.  Abstract
  • Cooperberg, MR; Moul, JW; Carroll, PR. The changing face of prostate cancer. Journal of Clinical Oncology. 2005;23:8146-8151.  Abstract
  • Dahm, P; Yang, BK; Salmen, CR; Moul, JW; Gan, TJ. Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients. The Journal of Urology. 2005;174:131-134.  Abstract
  • Gu, Y; Kim, KH; Ko, D; Srivastava, S; Moul, JW; McLeod, DG; Rhim, JS. Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. Anticancer research. 2005;25:1-8.  Abstract
  • Moul, JW. Screening for prostate cancer in military populations. Military medicine. 2005;170:905-914.  Abstract
  • Moul, JW; Saad, F. Low-risk prostate cancer patient: active treatment. Canadian Journal of Urology. 2005;12 Suppl 2:25-27.  Abstract
  • Moul, JW; Zlotta, AR. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. Bju International. 2005;95:285-290.  Abstract
  • Petrovics, G; Liu, A; Shaheduzzaman, S; Furusato, B; Sun, C; Chen, Y; Nau, M; Ravindranath, L; Chen, Y; Dobi, A; Srikantan, V; Sesterhenn, IA; McLeod, DG; Vahey, M; Moul, JW; Srivastava, S. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene: Including Oncogene Reviews. 2005;24:3847-3852.  Abstract
  • Semmes, OJ; Feng, Z; Adam, BL; Banez, LL; Bigbee, WL; Campos, D; Cazares, LH; Chan, DW; Grizzle, WE; Izbicka, E; Kagan, J; Malik, G; McLerran, D; Moul, JW; Partin, A; Prasanna, P; Rosenzweig, J; Sokoll, LJ; Srivastava, S; Srivastava, S; Thompson, I; Welsh, MJ; White, N; Winget, M; Yasui, Y; Zhang, Z; Zhu, L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clinical chemistry. 2005;51:102-112.  Abstract
  • Stewart, AJ; Scher, HI; Chen, MH; McLeod, DG; Carroll, PR; Moul, JW; D'Amico, AV. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. Journal of Clinical Oncology. 2005;23:6556-6560.  Abstract
  • Ward, JF; Moul, JW. Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Current Opinion in Urology. 2005;15:181-186.  Abstract
  • Ward, JF; Moul, JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Current Opinion in Urology. 2005;15:187-195.  Abstract
  • Ward, JF; Moul, JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nature Clinical Practice Urology. 2005;2:174-182.  Abstract
  • Ward, JF; Moul, JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clinical prostate cancer. 2005;4:38-44.  Abstract
  • Zhou, P; Chen, MH; McLeod, D; Carroll, PR; Moul, JW; D'Amico, AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. Journal of Clinical Oncology. 2005;23:6992-6998.  Abstract